Search for tag: "nsclc"

Tecentriq 於非小細胞肺癌第一線單獨使用整體存活期突破 20 個月! _Mark Socinski

IMpower110 是第一個 PD-L1 藥物 (Tecentriq) 被證實在第一線單獨使用相對於化療能夠大幅提高病患整體存活期 (20.2 mo vs 13.1 mo)。 可以提供無法接受化療或是無法申請到健保的病患一個有效的治療選擇。

From  Yi Chang on March 25th, 2021 0 likes 17 plays 0  

Tecentriq 於非小細胞肺癌第一線單獨使用整體存活期突破 20 個月! _Mark Socinski

IMpower110 是第一個 PD-L1 藥物 (Tecentriq) 被證實在第一線單獨使用相對於化療能夠大幅提高病患整體存活期 (20.2 mo vs 13.1 mo)。 可以提供無法接受化療或是無法申請到健保的病患一個有效的治療選擇。

From  Yi Chang on March 23rd, 2021 0 likes 11 plays 0  

Transforming the treatment of patients with advanced ALK+ NSCLC

Zoom Recording ID: 95846265211 UUID: dzXQD7usSyWLnh0/6HF0+w== Meeting Time: 2021-03-19T09:28:36Z

From  Mohammad Shafiqul Haque on March 19th, 2021 0 likes 15 plays

Down the Ocular Episode # 3 - VENTANA PD-L1 (SP142) Assay in NSCLC Part 2

This episode is part 2 in a series on the PD-L1 (SP142) assay in non small cell lung cancer. In this episode, Roche Tissue Diagnostics Medical and Scientific Affairs colleagues Bharathi Vennapusa, MD…

From  Bharathi Vennapusa on November 20th, 2020 0 likes 2 plays

Down the Ocular Episode # 2 - VENTANA PD-L1 (SP142) Assay in NSCLC Part 1

In this episode, Roche Tissue Diagnostics Medical and Scientific Affairs colleagues Bharathi Vennapusa, MD and Tabari Baker, PhD discuss the PD-L1 (SP142) assay in non-small cell lung cancer. Drs.…

From  Bharathi Vennapusa on November 20th, 2020 0 likes 5 plays

Setting The Standards for 1st Line ALK NSCLC Treatment

Interactive case-study focused webinar to learn about:• Differences in survival, CNS control and toxicity profiles among current andemerging treatment specifically in the landscape of 1L ALK+…

From  Kelda Tan on September 28th, 2020 0 likes 58 plays 0  

Global Vision: Immunotherapy in NSCLC (26May2020)

Prof Zhou Caicun (Shanghai Pulmonary Hospital, Tongji University School of Medicine Shanghai), Dr Ross Soo (National University Cancer Institute, Singapore) and a panel of Chinese oncologists were…

From  Kelda Tan on June 1st, 2020 0 likes 25 plays 0